Announced details
Healthcare, primarily healthcare institutions providing private-pay medical services
Product/service developed and provided by the company
The impact on consolidated results for the fiscal year ending March 2027 is expected to be immaterial. If any matter arises that should be reflected in the earnings forecast, the company will disclose it promptly once confirmed.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | AXON (Axon) |
| Relationship with the Company | Product/service developed and provided by the company |
| Launch date | 28 August 2026 (actual) |
| Applicable area | Healthcare, primarily healthcare institutions providing private-pay medical services |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 is expected to be immaterial. If any matter arises that should be reflected in the earnings forecast, the company will disclose it promptly once confirmed. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company is transitioning from its traditional labor-intensive consulting business to a scalable, product-based AI business in response to changes in the market structure accompanying the spread of generative AI.